These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 9526201)

  • 1. A resected case of Mycobacterium szulgai pulmonary disease.
    Tsuyuguchi K; Amitani R; Matsumoto H; Tanaka E; Suzuki K; Yanagihara K; Mizuno H; Hitomi S; Kuze F
    Int J Tuberc Lung Dis; 1998 Mar; 2(3):258-60. PubMed ID: 9526201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two cases of Mycobacterium szulgai pulmonary disease in the elderly].
    Hamada M; Kajiki A; Nagata N; Wakamatsu K; Komori M; Matsunaga K; Iwata Y; Ishimatsu A; Kitahara Y
    Kekkaku; 2005 May; 80(5):427-32. PubMed ID: 16083051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of pulmonary infectious disease due to Mycobacterium szulgai].
    Kobashi Y; Okimoto N; Soejima R
    Kekkaku; 1999 Oct; 74(10):715-9. PubMed ID: 10565131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary infection caused by Mycobacterium szulgai: a case report].
    Ikeue T; Watanabe S; Sugita T; Horikawa S; Suzuki Y; Nishiyama H; Maekawa N
    Kekkaku; 2002 May; 77(5):427-31. PubMed ID: 12073621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological study of cases with Mycobacterium szulgai infection].
    Iwanaga T; Kishikawa R; Ikeda T; Hirose T; Tsurutani H; Yoshida S
    Kekkaku; 1998 Oct; 73(10):579-84. PubMed ID: 9844345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preliminary results of initial short-term chemotherapy with INH, RMP and EMB in intermittent and biphasic administration (the 3 plus 6 experiment)].
    Anastasatu C; Bercea O; Barcan F; Stinghe R; Dinulică E; Marcovici M; Cristea M; Cărpinişan L; Gheorghiu M; Iancovici O; Ghinescu S
    Ftiziologia; 1974 May; 23(3):253-64. PubMed ID: 4842931
    [No Abstract]   [Full Text] [Related]  

  • 7. [Efficiency of interrupted therapy of tuberculosis (experimental study)].
    Drabkina RO; Ginzburg TS
    Antibiotiki; 1972 Jun; 17(6):555-60. PubMed ID: 5045922
    [No Abstract]   [Full Text] [Related]  

  • 8. Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974.
    Engbaek HC; Heckscher T; Højgaard C; Larsen SO; Rasmussen KN; Vergmann B
    Eur J Respir Dis; 1982 Mar; 63(2):84-93. PubMed ID: 7040100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Actual tuberculosis therapy. An attempt to simplify and to determine a schedule of tuberculosis chemotherapy].
    Virchow C
    Munch Med Wochenschr; 1969 Aug; 111(35):1717-22. PubMed ID: 4309162
    [No Abstract]   [Full Text] [Related]  

  • 11. Multifocal osteomyelitis due to Mycobacterium szulgai in a patient with chronic lymphocytic leukemia.
    Meyer JJ; Gelman SS
    J Infect; 2008 Feb; 56(2):151-4. PubMed ID: 18199481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urgent problems of antibacterial treatment of pulmonary tuberculosis].
    Pilipchuk NS
    Vrach Delo; 1981 Jan; (1):47-9. PubMed ID: 7010782
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chemotherapy of tuberculosis--compliance, side effects and incidence of recurrence].
    Brändli O; Häcki MA; Scheel A; Stiefel M
    Schweiz Med Wochenschr; 1983 Jan; 113(3):92-6. PubMed ID: 6828844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intermittent chemotherapy of pulmonary tuberculosis with rifampicin and ethambutol].
    Virsik K; Kruty R; Matula F; Badalik L
    Probl Tuberk; 1978 Oct; (10):28-30. PubMed ID: 714902
    [No Abstract]   [Full Text] [Related]  

  • 15. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The adverse effects of 2 therapy combinations (SM, PAS, INH, RMP, INH, EMB) in the intensive treatment phase of pulmonary tuberculosis].
    Knop P; Kindler U; Merholz T
    Med Welt; 1976 Feb; 27(8):389-90. PubMed ID: 1256308
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative studies of various antituberculosis drug regimens by means of serum antimycobacterial activity tests in man.
    Hokama S
    Jpn J Tuberc; 1967 Jul; 14(1):55-65. PubMed ID: 5300098
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapeutic results in lung diseases caused by atypical mycobacteria].
    Fischer P; Schilling W
    Z Erkr Atmungsorgane; 1984; 162(1):26-9. PubMed ID: 6202070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intermittent chemotherapy from the beginning or only after a period of daily administration? Quantitative bacteriological study at the initial phase of chemotherapy with INH + RMP + EMB in daily or intermittent administration].
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1977; 26(4):193-205. PubMed ID: 204971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of pulmonary infection caused by Mycobacterium szulgai].
    Haranaga S; Sato Y; Tohyama M; Toyama M; Ishimine T; Miyara T; Shinzato T; Higa F; Tateyama M; Saito A
    Kekkaku; 2002 May; 77(5):421-5. PubMed ID: 12073620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.